Second state in the USA stocks Impavido (miltefosine) for Leishmaniasis and off-label emergency use for treating Primary Amebic Meningoencephalitis (PAM)

July 28, 2016

South Carolina because the second state after Texas to participate in a non-charge consignment program from Profounda in an effort to make the drug more readily available in times of need.  Having the product available at multiple sites will allow treatment to start sooner when needed.

 

 

Please reload

Featured Posts

CDC Video showing N.Fowleri

July 21, 2017

1/4
Please reload

Recent Posts

October 6, 2017

Please reload

Archive
Please reload

Search By Tags
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

 Impavido® (miltefosine) is an FDA-approved treatment for cutaneous,  mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO